产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
首页 制药产品大全 药品制剂 Repaglinide tab...

Repaglinide tablet

2025-06-20
北京市

产品详情

Repaglinide tablet
内分泌及代谢类制剂
Repaglinide
中国,北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

产品描述

Introduction: Repaglinide is a non-sulfonylurea insulin secretory agent, and is one of the "five golden flowers" of oral hypoglycemic drugs. It is characterized by quick action, short action time, and belongs to the ultra-short action, so it is called the dietary blood glucose regulator.It was listed in China in 2000 and has entered the category B of medical insurance.

Indications: mainly for diet control, weight loss and exercise can not effectively control the hyperglycemia of type 2 diabetes (non-insulin-dependent) patients.

Direction and Dosage: Take before meals. Dosage varies from person to person to control blood sugar.When patients self-monitor blood glucose and/or urine glucose, medical staff should monitor blood glucose regularly to determine the minimum effective dose of medication for patients.Usually take this medicine within 15 minutes before meal, the time of taking the medicine can also be controlled within 0-30 minutes before meal.Please refer to the instruction manual for details.

Adverse reactions: immune system disorders, metabolism and nutrition disorders, eye abnormalities, heart diseases, gastrointestinal disorders, liver and gallbladder disorders, skin and subcutaneous tissue abnormalities, etc.

Taboo:

• Patients with known allergy to repaglinide or any of the excipients in repaglinide

• Patients with type 1 diabetes (insulin dependent -IDDM, C-peptide negative diabetes)

• Patients with diabetic ketoacidosis with or without coma

• Severe abnormal liver function

• Accompanied by the use of Gefebezies

Caution: see using story-telling for details.

北京北陆药业股份有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

Founded in 1992, Beilu is mainly engaged in the research & development, production and sales of pharmaceutical products. It is high-tech innovation company with core competence in the Contrast Media domestic. It has around 650 employees with 0.82 Bn/¥ revenue in 2019. Beilu provides complete Contrast Media products suitable for X-Ray and Magnetic Resonance Imaging (MRI), and it is the leading manufacturer in the Contrast Media field in China. It is one of the 1st batches of listed enterprises in GEM of SZSE (Ticker: 300016.SZ) in China.   Beilu's main products are Contrast Media, Anti-anxiety traditional Chinese medicine, and Anti-diabetic drugs to benefit people and improve their quality of life. Contrast Media are widely used to improve pictures of the inside of the body produced by X-rays, computed tomography (CT), magnetic resonance (MR) imaging, etc. Anti-anxiety traditional Chinese medicine is the original product with Chinese patent to contribute to improving the physical and mental status. And Anti-diabetic drugs are hypoglycemic drugs for the treatment of type 2 diabetes.
业务类型:
成立日期:
年营业额:
主营产品类别: